Sign up


Match Document Document Title
8586045 Methods of using anti-CGRP antagonist antibodies  
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot...
8586043 Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1  
The present invention relates to methods for the treatment, the prognostic assessment and the detection of breast cancer.
8586037 Antibodies against IL-17BR  
The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis...
8586036 Methods for the treatment of IL-1β related diseases  
Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia,...
8586716 EPHB3-specific antibody and uses thereof  
EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
8586035 Use of IL-23 antagonists for treatment of infection  
Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
8586034 Cytomegalovirus disintegrin-like peptides  
The present invention relates to methods and compositions for inhibiting the entry of viruses, such as herpesviruses into a host cell. A conserved viral integrin-binding gB disintegrin-like domain...
8580258 Treatment of tumors using specific anti-L1 antibody  
The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
8580253 Immunomodulating compositions and methods of use  
This invention is directed to β-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The β-1-6-glucans of certain embodiments of t...
8580529 Diagnosis of collagen IX destruction  
A method for detecting or monitoring the presence of protein fragments, cleaved at novel cleaving sites near the N-terminal part of the collagen IX alpha 1 chain, close to the C-terminal part of...
8580927 Engineered antibody constant domain molecules  
Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining...
8580257 Antibodies that specifically block the biological activity of kidney associated antigen 1 (KAAG1)  
Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain...
8580255 Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody  
The present invention provides compositions and methods for the treatment of autoimmune diseases, in particular rheumatoid arthritis. Compounds which function as antagonists of Toll-like Receptor 2...
8580256 Stabilized anti-hepatitis B (HBV) antibody formulations  
The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to...
8580744 Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms  
A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method...
8580259 Human monoclonal antibodies to BTLA and methods of use  
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the...
8580254 Anti-IGF antibodies  
Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1...
8574572 Method of treating pulmonary disease by administering an antibody to G-CSF receptor  
The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of...
8574571 Methods and compositions for modulating wound repair  
The present invention relates to a method of modulating repair of a wound. The method includes modulating expression and/or activity of Flightless I in cells involved in repair of the wound.
8574583 AAV capsid library and AAV capsid proteins  
Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating a library of recombinant adeno-associated viral capsid proteins are also provided.
8574858 Autoantibody enhanced immunoassays and kits  
The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies...
8574315 Electrospun structures and methods for forming and using same  
The present invention relates to structures that contain one or more fiber and/or nanofiber structures where such structures can be formed on a wide variety of structures or surfaces (e.g.,...
8574580 Monoclonal antibodies that recognize neurospheres or neural progenitor cells  
Method for generating monoclonal antibodies that recognize progenitor cells. Said method comprises immunization of an Armenian hamster with neurospheres obtained from olfactory bulb cells from a...
8574573 Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders  
The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically ...
8568725 Method of treating transplant rejection with an anti-CD40 antibody  
A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic...
8568718 Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same  
The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the...
8568717 Single domain antibodies capable of modulating BACE activity  
Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of...
8568721 Method of treating rheumatoid arthritis with an anti-IL-6R antibody  
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6...
8568778 Multiparticulate form of administration, comprising nucleic acid-containing mucoadhesive active ingredients, and method for producing said form of administration  
The invention relates to an oral, multiparticulate form of administration, comprising pellets in the size ranging from 50 to 2500 $g(m)m which are substantially constituted of a) an inner matrix...
8568995 Methods for assessing modified LDL immune complexes in subjects having or at risk of coronary artery disease  
The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease...
8568720 High concentration antibody-containing liquid formulation  
The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during...
8563694 Fully human antibodies to BTLA  
The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its...
8563520 Treatment of ocular disease with inhibitors of alpha2 macroglobulin protein  
The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or α2 ...
8562993 Methods for treating GI syndrome and graft versus host disease  
We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial...
8562994 Human-murine chimeric antibodies against respiratory syncytial virus  
This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial...
8562985 Antibodies to c-Met  
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit...
8563696 Antibody specifically binding to c-Met  
Antibodies specifically binding to c-Met protein, hybridoma cell lines, and compositions comprising the antibodies are disclosed herein. Methods of making and using the antibodies and compositions...
8562995 Neoplasm specific antibodies and uses thereof  
The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.
8562984 Methods of treatment using anti-IL-20 antibodies  
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its...
8557245 Methods for treating bone cancer by administering a nerve growth factor antagonist antibody  
The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth...
8557967 Anti-interferon-α antibodies  
The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention f...
8557244 Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody  
This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof....
8557240 Method for the treatment of inflammatory disorders  
A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable...
8557239 Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23  
The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
8557238 EG-VEGF nucleic acids and polypeptides and methods of use  
The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells...
8551476 SP35 antibodies and uses thereof  
Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35...
8552157 c-Kit antibodies and uses thereof  
This invention is directed to antibodies that specifically bind to an extracellular domain of human c-Kit, pharmaceutical compositions comprising these antibodies, and their use in treating cancer.
8551477 Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same  
T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and...
8552154 Anti-PD-L1 antibodies and uses therefor  
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing,...
8551485 Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells  
The present invention describes humanized antibodies that target CD40, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters...